Primary objective is to evaluate the response rates and clinical benefits of letrozole + goserelin in premenopausal patients versus letrozole alone in postmenopausal patients with metastatic breast cancer as first line hormonal therapy
Name: Letrozole ,GoserelinDescription: Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)Type: Drug
letrozole goserelin plus letrozole
There is one SNP
In a study, when 67 postmenopausal patients with hormone receptor positive metastatic breast cancer were treated with letrozole, median TTP was significantly longer in patients with the rs4646 variant of intratumoral CYP19, a SNP in 3'-UTR, compared with normal CYP19 (17.2 months versus 6.4 months; P=0.02).